Get the latest tech news
FDA approves at-home Alzheimer's shot to effectively slow disease | Leqembi, following study data showing that it could slow cognitive decline and help clear amyloid plaques.
The US Food and Drug Administration (FDA) has approved a new version of an Alzheimer’s disease drug that can be given as a quick at-home weekly injection, offering patients a far more convenient option than lengthy infusion-center visits. It will be widely available from October 6, 2025.
Leqembi (lecanemab-irmb) was first approved in 2023 as an intravenous (IV) infusion for patients with early Alzheimer’s disease (AD), following study data showing that it could slow cognitive decline and help clear amyloid plaques. For families navigating early AD, Leqembi Iqlik means fewer clinic visits, reduced healthcare costs and the possibility of managing treatment entirely at home. It also stands to relieve pressure on infusion centers and medical staff, while broadening eligibility to patients in rural areas and regions without easy access to IV clinics.
Or read this on r/tech
